Ester in t'Groen

In this discussion, Ester in t'Groen, the Medical Affairs Head for Hematology at Johnson & Johnson, shares her expertise following the ASH Annual Meeting. She dives into their robust hematology portfolio, highlighting the evolution of daratumumab and the exciting results of the MajesTEC-3 trial. Ester discusses how CAR-T therapies are transforming patient care and presents compelling real-world evidence that shows significant benefits for blood cancer patients. She also previews what's on the horizon for 2026, including next-gen therapies and combination strategies.